Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an announcement.
On May 15, 2026, XORTX Therapeutics Inc. filed a Form 6-K for May 2026, releasing unaudited condensed interim consolidated financial statements and management discussion and analysis for the quarter ended March 31, 2026. The filing also included CEO and CFO certifications, underscoring the company’s ongoing compliance with U.S. and Canadian securities disclosure requirements and providing investors with updated visibility into its financial position and operating expenses.
The March 31, 2026 statements show total assets of $2.14 million, down from $2.68 million at year-end 2025, driven by a sharp decline in cash to $250,275 and lower property and equipment values. Liabilities rose to $0.86 million, eroding shareholders’ equity to $1.28 million, while the company recorded a quarterly net loss driven by research, development, professional fees and public company costs, highlighting continued funding needs and execution risk for stakeholders in its drug development programs.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and sustained cash burn), only partly offset by very low leverage and improving loss trends. Technicals are neutral-to-mixed, and valuation is difficult to support with a negative P/E and no dividend yield.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a Calgary-based biopharmaceutical company focused on developing therapies, including intellectual property and drug candidates, aimed at treating progressive kidney disease and related metabolic conditions. The firm is listed in the United States as a foreign private issuer and reports its results under International Financial Reporting Standards in U.S. dollars.
Average Trading Volume: 2,602
Technical Sentiment Signal: Sell
Current Market Cap: C$4.93M
See more insights into XRTX stock on TipRanks’ Stock Analysis page.